Improving diagnosis and treatment of head and neck cancer through epigenetic profiling
Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer
This study is testing if looking at specific changes in genes can help doctors better diagnose and treat head and neck cancer in adults who haven't had treatment yet.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Milan, MI) |
| Trial ID | NCT06706973 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of epigenetic marks in head and neck cancer (HNC) to identify potential therapeutic targets. It focuses on distinguishing between HPV-positive and HPV-negative HNC by analyzing unique histone modifications. The research aims to understand how these epigenetic changes contribute to tumorigenesis in HNC, which could lead to more effective treatment strategies. Participants will include adults diagnosed with primary squamous cell carcinoma of the oral cavity, larynx, oropharynx, who have not received prior treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with treatment-naïve primary squamous cell carcinoma of the head and neck.
Not a fit: Patients who have previously undergone radiotherapy, chemotherapy, or immunotherapy for head and neck cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and targeted therapies for patients with head and neck cancer.
How similar studies have performed: Other studies have shown promise in targeting epigenetic modifications in various cancers, suggesting potential success for this approach in head and neck cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:• Age: Adults aged ≥ 18 years diagnosed with HNC * Sex: Both male and female * Human papilloma virus (HPV) test: Both positive and negative. * Tumor: primary tumors, treatment naïve, squamous cell carcinoma * Cancer stage: I-IV * Anatomic location: oral cavity, larynx, oropharynx * Tumor fragments not required for diagnostics Exclusion Criteria: * Previous radiotherapy, chemotherapy or immunotherapy for HNC * Unable to provide written informed consent
Where this trial is running
Milan, MI
- European Institute of oncology — Milan, Mi, Italy (Recruiting)
Study contacts
- Principal investigator: Susanna Chiocca — Istituto Europeo di Oncologia
- Study coordinator: Susanna Chiocca, Doctor
- Email: susanna.chiocca@ieo.it
- Phone: 00390257488835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.